Galectin director granted 60,000 stock options

Galectin Therapeutics (GALT) director granted stock options Galectin Therapeutics director Gilbert F. Amelio reported receiving stock options for 60,000 shares of the company’s common stock on January 16, 2026.

Rhea-AI Filing Summary

Galectin Therapeutics (GALT) director granted stock options

Galectin Therapeutics director Gilbert F. Amelio reported receiving stock options for 60,000 shares of the company’s common stock on January 16, 2026. The options have an exercise price of $3.04 per share and were issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. According to the filing, the options vest 100% on December 31, 2026, meaning they become fully exercisable on that date. Following this grant, Amelio beneficially owns 60,000 stock options directly.

Insider Trade Summary

Grant/Award: 60,000 shares

Grant/Award 1 txn

Insider AMELIO GILBERT F

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	60,000	$0.00	$0.00

Holdings After Transaction: Stock option (right to buy) — 60,000 contracts (Direct)

Footnotes (2)

1. F1. The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.
2. F2. The options vest 100% on December 31, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Galectin Therapeutics (GALT) report in this Form 4?

The filing reports that director Gilbert F. Amelio received a grant of 60,000 stock options for Galectin Therapeutics common stock on January 16, 2026.

What is the exercise price of the Galectin Therapeutics (GALT) stock options granted to Gilbert F. Amelio?

The stock options granted to Gilbert F. Amelio have an exercise price of $3.04 per share for Galectin Therapeutics common stock.

When do Gilbert F. Amelio’s Galectin Therapeutics (GALT) stock options vest?

The options reported in the filing vest 100% on December 31, 2026, after which they become fully exercisable.

How many Galectin Therapeutics (GALT) derivative securities does Gilbert F. Amelio own after this transaction?

After the reported grant, Gilbert F. Amelio beneficially owns 60,000 stock options directly, as stated in the filing.

Under which plan were the Galectin Therapeutics (GALT) options to Gilbert F. Amelio granted?

The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan, according to the footnotes.

What is the nature of ownership for Gilbert F. Amelio’s Galectin Therapeutics (GALT) options?

The Form 4 lists the 60,000 stock options as held with direct (D) ownership by Gilbert F. Amelio.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/21/2026 - 04:45 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

AMELIO GILBERT F

(Last) (First) (Middle)

4960 PEACHTREE INDUSTRIAL BLVD

SUITE 240

(Street)

NORCROSS GA 30071

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GALECTIN THERAPEUTICS INC [ GALT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)(1)	$3.04	01/16/2026		A		60,000		(2)	01/16/2036	Common Stock	60,000	$0	60,000	D

Explanation of Responses:

1. The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

2. The options vest 100% on December 31, 2026.

	Jack W. Callicutt, by power of attorney	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.